Literature DB >> 9096399

Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa.

R Bordet1, S Ridray, S Carboni, J Diaz, P Sokoloff, J C Schwartz.   

Abstract

In rats with unilateral lesions of the nigrostriatal dopamine pathway with 6-hydroxydopamine, the motor stimulating effects of levodopa, an indirect dopamine receptor agonist, evidenced by contraversive rotations, become enhanced upon repeated intermittent administration. However, the mechanisms of this behavioral sensitization are essentially unknown. We show that development of sensitization is accompanied by a progressive appearance of D3 receptor mRNA and binding sites, visualized by in situ hybridization and 7-[3H] hydroxy-N,N-di-n-propyl-2-aminotetralin autoradiography, respectively, occurring in the denervated caudate putamen, a brain area from which this receptor subtype is normally absent. Development and decay of these two processes occur with closely parallel time courses, whereas there were no marked changes in D1 or D2 receptor mRNAs. D3 receptor induction by levodopa is mediated by repeated D1 receptor stimulation, since it is prevented by the antagonist SCH 33390 and mimicked by the agonist SKF 38393, but not by two D2 receptor agonists. The enhanced behavioral response to levodopa is mediated by the newly synthesized D3 receptor, since it is antagonized by nafadotride, a preferential D3 receptor antagonist, in low dosage, which has no such effect before D3 receptor induction. D3 receptor induction and behavioral sensitization are also accompanied by a sustained enhancement of prodynorphin mRNA level and a progressively decreasing expression of the preprotachykinin gene. We propose that imbalance between dynorphin and substance P release from the same striatonigral motor efferent pathway, related to D3 receptor induction, is responsible for behavioral sensitization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096399      PMCID: PMC20375          DOI: 10.1073/pnas.94.7.3363

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

2.  Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical studies.

Authors:  I Christensson-Nylander; M Herrera-Marschitz; W Staines; T Hökfelt; L Terenius; U Ungerstedt; C Cuello; W H Oertel; M Goldstein
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

3.  L-dopa activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra.

Authors:  G S Robertson; D G Herrera; M Dragunow; H A Robertson
Journal:  Eur J Pharmacol       Date:  1989-01-02       Impact factor: 4.432

4.  Continuous and intermittent levodopa differentially affect basal ganglia function.

Authors:  J L Juncos; T M Engber; R Raisman; Z Susel; F Thibaut; A Ploska; Y Agid; T N Chase
Journal:  Ann Neurol       Date:  1989-05       Impact factor: 10.422

5.  Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions.

Authors:  J M Trugman; G F Wooten
Journal:  J Neurosci       Date:  1987-09       Impact factor: 6.167

6.  Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  I J Mitchell; C E Clarke; S Boyce; R G Robertson; D Peggs; M A Sambrook; A R Crossman
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

7.  Extensive co-occurrence of substance P and dynorphin in striatal projection neurons: an evolutionarily conserved feature of basal ganglia organization.

Authors:  K D Anderson; A Reiner
Journal:  J Comp Neurol       Date:  1990-05-15       Impact factor: 3.215

8.  Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis.

Authors:  C R Gerfen; J F McGinty; W S Young
Journal:  J Neurosci       Date:  1991-04       Impact factor: 6.167

9.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

Authors:  C R Gerfen; T M Engber; L C Mahan; Z Susel; T N Chase; F J Monsma; D R Sibley
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

10.  Electrophysiological evidence for a non-opioid interaction between dynorphin and GABA in the substantia nigra of the rat.

Authors:  B C Robertson; D W Hommer; L R Skirboll
Journal:  Neuroscience       Date:  1987-11       Impact factor: 3.590

View more
  68 in total

1.  Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders.

Authors:  Pierre Sokoloff; Olivier Guillin; Jorge Diaz; Patrick Carroll; Nathalie Griffon
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 2.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 3.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 4.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

5.  Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.

Authors:  Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

6.  Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment.

Authors:  M Rafiuddin Ahmed; Evgeny Bychkov; Vsevolod V Gurevich; Jeffrey L Benovic; Eugenia V Gurevich
Journal:  J Neurochem       Date:  2007-11-07       Impact factor: 5.372

7.  Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay Riddle; Suzy A Griffin; Peter Grundt; Amy Hauck Newman; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

8.  Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay R Riddle; Suzy A Griffin; Wenhua Chu; Suwanna Vangveravong; Janet Neisewander; Robert H Mach; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

9.  Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats.

Authors:  Elissa M Strome; Athanasios P Zis; Doris J Doudet
Journal:  J Psychiatry Neurosci       Date:  2007-05       Impact factor: 6.186

10.  Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.

Authors:  Jean-Christophe Corvol; Marie-Paule Muriel; Emmanuel Valjent; Jean Féger; Naïma Hanoun; Jean-Antoine Girault; Etienne C Hirsch; Denis Hervé
Journal:  J Neurosci       Date:  2004-08-04       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.